Investor Relations : BioMarin

Latest Events

41st Annual JP Morgan Healthcare Conference
Listen to Webcast

Press Releases

Jan 8, 2023

BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis

- Mean Annualized Bleed Rate Reduced by 80% from Baseline and Factor VIII Usage Reduced by 94% in Year 3 Compared to Baseline - 92% of Patients off Prophylaxis at the End of Year 3 - First...

All Press Releases

Quarterly Results

Doc

BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN^®)

Call

Listen to the 3Q22 CC

All Financial Information

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.

Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

Learn More

Investor Relations
415-455-7558
IR@BMRN.com

Media & Press
415-455-7451
corporatecommunications2@BMRN.com

Email Alerts